ArticleActa parasitologica2026
Evaluation of Human-Approved Active Pharmaceutical Ingredients Against Lactate Dehydrogenase from Theileria annulata.
Article in Acta parasitologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundTheileriosis, a tick-borne disease caused by Theileria annulata, leads to global economic losses in livestock, emphasizing an urgent need for the identification of new therapeutic agents with alternative mechanisms of action due to rising buparvaquone resistance combined with climate-driven spread. T. annulata lactate dehydrogenase (TaLDH) has been selected as a promising target in the current study. As approximately half of the FDA-approved veterinary drugs are shared with human medicine, integrating drug repurposing has gained importance as an emerging strategy for the management of tick-borne diseases. MethodsIn this study, in vitro and in silico approaches are integrated to screen 21 Active Pharmaceutical Ingredients (APIs) from FDA-approved drugs against TaLDH in the context of drug repurposing. Results Six of 21 the APIs showed ≥ 60% inhibition against TaLDH (over 95% purity), particularly the proton pump inhibitor omeprazole, which exhibited both the highest inhibition percentage (73.36%) and the lowest binding energy (- 6.36 kcal/mol), with a consistency between experimental and computational results. To our knowledge, this study is the first to evaluate FDA-approved human therapeutics as potential TaLDH inhibitors. Conclusion This preliminary in vitro enzymatic inhibition study suggests omeprazole as a potential therapeutic agent for theileriosis. However, comprehensive pharmacokinetic and pharmacodynamic analyses will further validate and advance these promising findings. Furthermore, APIs with ≥ 60% inhibition of TaLDH may serve as promising leads for the future development of more potent anti-theilerial agents through targeted derivatization and lead optimization. In alignment with the One Health framework, evaluating human-approved active pharmaceutical ingredients as veterinary therapeutic against parasitic diseases may offer a sustainable, time and cost-efficient strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.